tetano
Editor, Senior Moderator
Biochemistry
. 2024 Jan 8.
doi: 10.1021/acs.biochem.3c00536. Online ahead of print. Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants
Alysia J Kohlbrand[SUP] 1 [/SUP], Ryjul W Stokes[SUP] 1 [/SUP], Banumathi Sankaran[SUP] 2 [/SUP], Seth M Cohen[SUP] 1 [/SUP]
Affiliations
Vital to the treatment of influenza is the use of antivirals such as Oseltamivir (Tamiflu) and Zanamivir (Relenza); however, antiviral resistance is becoming an increasing problem for these therapeutics. The RNA-dependent RNA polymerase acidic N-terminal (PA[SUB]N[/SUB]) endonuclease, a critical component of influenza viral replication machinery, is an antiviral target that was recently validated with the approval of Baloxavir Marboxil (BXM). Despite its clinical success, BXM has demonstrated susceptibility to resistance mutations, specifically the I38T, E23K, and A36 V mutants of PA[SUB]N[/SUB]. To better understand the effects of these mutations on BXM resistance and improve the design of more robust therapeutics, this study examines key differences in protein-inhibitor interactions with two inhibitors and the I38T, E23K, and A36 V mutants. Differences in inhibitor binding were evaluated by measuring changes in binding to PA[SUB]N[/SUB] using two biophysical methods. The binding mode of two distinct inhibitors was determined crystallographically with both wild-type and mutant forms of PA[SUB]N[/SUB]. Collectively, these studies give some insight into the mechanism of antiviral resistance of these mutants.
. 2024 Jan 8.
doi: 10.1021/acs.biochem.3c00536. Online ahead of print. Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants
Alysia J Kohlbrand[SUP] 1 [/SUP], Ryjul W Stokes[SUP] 1 [/SUP], Banumathi Sankaran[SUP] 2 [/SUP], Seth M Cohen[SUP] 1 [/SUP]
Affiliations
- PMID: 38190441
- DOI: 10.1021/acs.biochem.3c00536
Vital to the treatment of influenza is the use of antivirals such as Oseltamivir (Tamiflu) and Zanamivir (Relenza); however, antiviral resistance is becoming an increasing problem for these therapeutics. The RNA-dependent RNA polymerase acidic N-terminal (PA[SUB]N[/SUB]) endonuclease, a critical component of influenza viral replication machinery, is an antiviral target that was recently validated with the approval of Baloxavir Marboxil (BXM). Despite its clinical success, BXM has demonstrated susceptibility to resistance mutations, specifically the I38T, E23K, and A36 V mutants of PA[SUB]N[/SUB]. To better understand the effects of these mutations on BXM resistance and improve the design of more robust therapeutics, this study examines key differences in protein-inhibitor interactions with two inhibitors and the I38T, E23K, and A36 V mutants. Differences in inhibitor binding were evaluated by measuring changes in binding to PA[SUB]N[/SUB] using two biophysical methods. The binding mode of two distinct inhibitors was determined crystallographically with both wild-type and mutant forms of PA[SUB]N[/SUB]. Collectively, these studies give some insight into the mechanism of antiviral resistance of these mutants.